Magnus T. Dillon

London, ENG SW73RP, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma-UK Tertiary Cancer Centre Experience.

Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma-UK Tertiary Cancer Centre Experience.

Journal: Cancers

Published: March 30, 2026

Project Optimus for Radiation Therapy-Drug Combinations: Moving Beyond the Maximum Tolerated Dose.

Project Optimus for Radiation Therapy-Drug Combinations: Moving Beyond the Maximum Tolerated Dose.

Journal: International journal of radiation oncology, biology, physics

Published: November 13, 2025

Interfaces Between the DNA Damage Response and Anti-cancer Immunity.

Interfaces Between the DNA Damage Response and Anti-cancer Immunity.

Journal: Cancer journal (Sudbury, Mass.)

Published: April 16, 2025

Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial.

Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial.

Journal: Nature communications

Published: October 31, 2024

The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models.

The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models.

Journal: Nature communications

Published: March 18, 2024

Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy.

Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy.

Journal: Nature communications

Published: January 05, 2024

Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.

Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.

Journal: The Journal of clinical investigation

Published: August 31, 2023

OX40 and 4-1BB delineate distinct immune profiles in sarcoma.

OX40 and 4-1BB delineate distinct immune profiles in sarcoma.

Journal: Oncoimmunology

Published: May 13, 2022

Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.

Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.

Journal: Journal for immunotherapy of cancer

Published: February 06, 2022

Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model development.

Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model development.

Journal: eLife

Published: August 24, 2021

Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer.

Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer.

Journal: Journal for immunotherapy of cancer

Published: January 14, 2021

Inflammatory microenvironment remodelling by tumour cells after radiotherapy.

Inflammatory microenvironment remodelling by tumour cells after radiotherapy.

Journal: Nature reviews. Cancer

Published: February 12, 2020

Showing 1-12 of 25

Last Updated: 09/26/2026